Research programme: extended-release/abuse-resistant pain therapeutics - Collegium PharmaceuticalAlternative Names: COL-196
Latest Information Update: 13 Jun 2015
At a glance
- Originator Collegium Pharmaceutical
- Class Analgesics
- Mechanism of Action Opioid receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Pain